mitotane has been researched along with Angiogenesis, Pathologic in 2 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Several important questions remain to be addressed such as the optimal dose and most effective dosing interval, when to use the metronomic approach in the natural history of the disease, the choice of cytotoxic drugs, and the most efficacious way to integrate metronomic chemotherapy with standard therapy protocols." | 2.47 | Metronomic therapy concepts in the management of adrenocortical carcinoma. ( Ardito, A; Bellini, E; Berruti, A; Daffara, F; Perotti, P; Saini, A; Sperone, P; Terzolo, M, 2011) |
| "Adrenocortical carcinoma is a rare malignancy with poor prognosis and limited response to chemotherapy." | 1.42 | Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. ( Cortez, MA; Cote, GJ; Fuentes-Mattei, E; Habra, MA; Hai, T; Hofmann, MC; Jimenez, C; Lee, MH; Ozsari, L; Pagliaro, L; Phan, LM; Sircar, K; Velazquez-Torres, G; Verhaak, R; Wood, CG; Wu, W; Yeung, SC; Zheng, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phan, LM | 1 |
| Fuentes-Mattei, E | 1 |
| Wu, W | 1 |
| Velazquez-Torres, G | 1 |
| Sircar, K | 1 |
| Wood, CG | 1 |
| Hai, T | 1 |
| Jimenez, C | 1 |
| Cote, GJ | 1 |
| Ozsari, L | 1 |
| Hofmann, MC | 1 |
| Zheng, S | 1 |
| Verhaak, R | 1 |
| Pagliaro, L | 1 |
| Cortez, MA | 1 |
| Lee, MH | 1 |
| Yeung, SC | 1 |
| Habra, MA | 1 |
| Berruti, A | 1 |
| Sperone, P | 1 |
| Bellini, E | 1 |
| Daffara, F | 1 |
| Perotti, P | 1 |
| Ardito, A | 1 |
| Saini, A | 1 |
| Terzolo, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma[NCT03612232] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-06-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitotane and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Metronomic therapy concepts in the management of adrenocortical carcinoma.
Topics: Administration, Metronomic; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplast | 2011 |
1 other study available for mitotane and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
Topics: Adenoma; Adrenal Cortex Neoplasms; Adult; Aged; Aged, 80 and over; Anilides; Animals; Antineoplastic | 2015 |